PCR Journal Club

Which ballooning technique is best after main vessel stenting in bifurcation PCI? This two-part study compares two key approaches: PKP (POT, kissing balloon inflation, final POT) and PSP (POT, isolated side branch dilation, final POT) to determine the optimal strategy.

At two-year follow-up, the use of sirolimus-eluting cobalt-chromium DynamX Drug Eluting Coronary Bioadaptor System (Elixir Medical Corporation) resulted in fewer target lesion failure (TLF) compared with the Resolute Onyx contemporary drug-eluting stent.

Due to a lack of randomised evidence, this randomised controlled trial (RCT) aimed to compare the safety and efficacy of IVL and ELCA with RA in treating heavily calcified coronary lesions before drug-eluting stent implantation.

The present study compares a novel sirolimus-coated balloon with a clinically proven paclitaxel-coated balloon for the treatment of de novo coronary lesions, demonstrating non-inferiority in terms of angiographic late lumen loss at 6 months.

The aim of this pre-specified analysis of the ILUMIEN IV trial was to assess the relationship between post-PCI OCT parameters of suboptimal stent implantation and clinical outcomes.

This trial found that, in ACS patients undergoing PCI, DP-DES and BP-DES had similar patient-oriented outcomes at three years, but BP-DES had higher device-oriented composite outcomes, mainly due to increased TLR risk.

The trial aimed to establish the non-inferiority of QCA-guided PCI compared to IVUS-guided PCI with respect to the primary endpoint of TLF at 12 months, defined as a composite of cardiac death, target vessel MI, or ischemia-driven target lesion revascularization.

The 12-month outcomes of the BIOMAG-I first-in-human trial demonstrate a favorable safety profile for the third-generation magnesium scaffold and 38 % improved performance compared to its precursor. 

The purpose of the ROLEX Registry (Revascularization Of LEft main with resolute onyX) was to explore outcomes using a more contemporary drug eluting stent platform which is more suitable for LM PCI.

The HOST-REDUCE-POLYTECH-ACS trial was a randomised, parallel-group multicentre trial with a 2x2 factorial design testing two independent hypotheses, one of which was the non-inferiority of durable polymer drug-eluting stents (DP-DES) to biodegradable polymer drug-eluting stents (BP-DES) in patients with ACS. In this post-hoc analysis, the authors...